We are searching data for your request:
Upon completion, a link will appear to access the found materials.
The diabetes medication Avandia (active ingredient rosiglitazone) has not been approved in Germany since November 2010 because several studies have identified significant health risks when taking it. Given the cardiovascular risks and increased heart attacks, the European Medicines Agency had previously rated Avandia's benefit-risk balance as unfavorable. The health risks have not been confirmed in recent studies, but Avandia is currently no longer in use in this country. (fp)
(Image 1: Kwangmoo / fotolia.com)